Akebia Therapeutics (AKBA) Cash from Investing Activities Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -3,137.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,137.30% |
| Mar 31, 2026 | -140.26% |
| Dec 31, 2025 | -393,750.00% |
| Sep 30, 2025 | -3,750.00% |
| Jun 30, 2025 | -334.48% |
| Mar 31, 2022 | -100.57% |
| Jun 30, 2021 | 140.00% |
| Mar 31, 2021 | 8,039.18% |
| Dec 31, 2020 | 167.88% |
| Sep 30, 2020 | -304.74% |
| Jun 30, 2020 | -192.53% |
| Mar 31, 2020 | -99.78% |
| Dec 31, 2019 | 33.28% |
| Sep 30, 2019 | 121.51% |
| Jun 30, 2019 | 1,614.38% |
| Mar 31, 2019 | 788.48% |
| Dec 31, 2018 | 301.22% |
| Sep 30, 2018 | 124.49% |
| Jun 30, 2018 | 88.74% |
| Mar 31, 2018 | 113.47% |